Cargando…
Therapeutic strategies in epithelial ovarian cancer
Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309949/ https://www.ncbi.nlm.nih.gov/pubmed/22330607 http://dx.doi.org/10.1186/1756-9966-31-14 |
_version_ | 1782227586009530368 |
---|---|
author | Kim, Ayako Ueda, Yutaka Naka, Tetsuji Enomoto, Takayuki |
author_facet | Kim, Ayako Ueda, Yutaka Naka, Tetsuji Enomoto, Takayuki |
author_sort | Kim, Ayako |
collection | PubMed |
description | Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway. |
format | Online Article Text |
id | pubmed-3309949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33099492012-03-23 Therapeutic strategies in epithelial ovarian cancer Kim, Ayako Ueda, Yutaka Naka, Tetsuji Enomoto, Takayuki J Exp Clin Cancer Res Review Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway. BioMed Central 2012-02-13 /pmc/articles/PMC3309949/ /pubmed/22330607 http://dx.doi.org/10.1186/1756-9966-31-14 Text en Copyright ©2012 Kim et al; BioMed Central Ltd.2012 http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited |
spellingShingle | Review Kim, Ayako Ueda, Yutaka Naka, Tetsuji Enomoto, Takayuki Therapeutic strategies in epithelial ovarian cancer |
title | Therapeutic strategies in epithelial ovarian cancer |
title_full | Therapeutic strategies in epithelial ovarian cancer |
title_fullStr | Therapeutic strategies in epithelial ovarian cancer |
title_full_unstemmed | Therapeutic strategies in epithelial ovarian cancer |
title_short | Therapeutic strategies in epithelial ovarian cancer |
title_sort | therapeutic strategies in epithelial ovarian cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309949/ https://www.ncbi.nlm.nih.gov/pubmed/22330607 http://dx.doi.org/10.1186/1756-9966-31-14 |
work_keys_str_mv | AT kimayako therapeuticstrategiesinepithelialovariancancer AT uedayutaka therapeuticstrategiesinepithelialovariancancer AT nakatetsuji therapeuticstrategiesinepithelialovariancancer AT enomototakayuki therapeuticstrategiesinepithelialovariancancer |